BeyondSpring Inc - Asset Resilience Ratio
BeyondSpring Inc (BYSI) has an Asset Resilience Ratio of 18.41% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BeyondSpring Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how BeyondSpring Inc's Asset Resilience Ratio has changed over time. See BeyondSpring Inc (BYSI) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BeyondSpring Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BeyondSpring Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.78 Million | 18.41% |
| Total Liquid Assets | $4.78 Million | 18.41% |
Asset Resilience Insights
- Good Liquidity Position: BeyondSpring Inc maintains a healthy 18.41% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
BeyondSpring Inc Industry Peers by Asset Resilience Ratio
Compare BeyondSpring Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for BeyondSpring Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for BeyondSpring Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.41% | $4.78 Million | $25.93 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $34.31 Million | -- |
| 2023-12-31 | 0.78% | $193.00K | $24.81 Million | -5.44pp |
| 2022-12-31 | 6.21% | $2.87 Million | $46.22 Million | -31.44pp |
| 2021-12-31 | 37.65% | $30.74 Million | $81.65 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $117.04 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $7.06 Million | -- |
| 2017-12-31 | 9.36% | $3.07 Million | $32.83 Million | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-canc… Read more